Abstract
Background: Management of localized renal cell carcinoma (RCC) is challenged by inaccurate methods to assess the risk of recurrence and deferred detection of relapse and residual disease after radical or partial nephrectomy. Circulating tumor DNA (ctDNA) has been proposed as a potential biomarker in RCC.
Purpose: Conduction of an observational study to evaluate the validity of ctDNA as a biomarker of the risk of recurrence and subclinical residual disease to improve postoperative surveillance.
Material and methods: Urine and blood will be prospectively collected before and after surgery of the primary tumor from up to 500 patients until 5 years of follow-up. ctDNA analysis will be performed using shallow whole genome sequencing and cell-free methylated DNA immunoprecipitation sequencing. ctDNA levels in plasma and urine will be correlated to oncological outcomes. Residual blood and urine as well as tissue biopsies will be biobanked for future research.
Interpretation: Results will pave the way for future ctDNA-guided clinical trials aiming to improve RCC management.
Funder
Lundbeck Foundation
Kræftens Bekæmpelse
Danmarks Frie Forskningsfond
Publisher
MJS Publishing, Medical Journals Sweden AB
Reference10 articles.
1. Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71. https://doi.org/10.1002/cncr.11234
2. Azawi NH, Tesfalem H, Mosholt KSS, et al. Recurrence rates and survival in a Danish cohort with renal cell carcinoma. Dan Med J [Internet]. 2016;63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27034180 [cited: 2023-11-08]
3. Larribère L, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. Cancers. 2021;13:5698. https://doi.org/10.3390/cancers13225698
4. Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379:1754–65. https://doi.org/10.1056/NEJMra1706174
5. Geertsen L, Koldby KM, Thomassen M, Kruse T, Lund L. Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature. Eur Urol Open Sci. 2022;37:27–35. https://doi.org/10.1016/j.euros.2021.12.006
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献